The current treatment approach in rheumatoid arthritis (RA) follows a stepwise management, starting from early introduction of conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs), moving to biological (b) DMARDs and targeted synthetic (ts) DMARDs. In the last few years, new drugs with different mechanisms of action have demonstrated their efficacy in treating such a disabling condition, and their approval, along with other more "experienced" treatments, has established their effectiveness on disease activity, damage accrual prevention, patients' quality of life improvement, confirming their safety profile. Moreover, new molecular pathways are under investigation as potential targets of new advanced therapies. Clinicians' capability of stratifying treatment strategies and decisions has improved, with several new tools for the optimisation of long-term management of RA; however, a high proportion of patients are refractory to the available drugs. Finally, as RA is a systemic disease, the knowledge in multi-systemic complications of the disease has grown, as well as the possibility in improving extra-articular manifestations of the disease, although certain drugs have potentially relevant non-articular effects, which need to be monitored. This narrative review summarises the most relevant studies published over the last year in the field of treatment of RA, with the major aim to let clinicians and researchers reflect on "what is new", "what is effective" and "what is safe".

Silvagni, E., Di Battista, M., Bonifacio, A., Zucchi, D., Governato, G., Scire, C. (2019). One year in review 2019: novelties in the treatment of rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 37(4), 519-534.

One year in review 2019: novelties in the treatment of rheumatoid arthritis

Scire C. A.
Ultimo
2019

Abstract

The current treatment approach in rheumatoid arthritis (RA) follows a stepwise management, starting from early introduction of conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs), moving to biological (b) DMARDs and targeted synthetic (ts) DMARDs. In the last few years, new drugs with different mechanisms of action have demonstrated their efficacy in treating such a disabling condition, and their approval, along with other more "experienced" treatments, has established their effectiveness on disease activity, damage accrual prevention, patients' quality of life improvement, confirming their safety profile. Moreover, new molecular pathways are under investigation as potential targets of new advanced therapies. Clinicians' capability of stratifying treatment strategies and decisions has improved, with several new tools for the optimisation of long-term management of RA; however, a high proportion of patients are refractory to the available drugs. Finally, as RA is a systemic disease, the knowledge in multi-systemic complications of the disease has grown, as well as the possibility in improving extra-articular manifestations of the disease, although certain drugs have potentially relevant non-articular effects, which need to be monitored. This narrative review summarises the most relevant studies published over the last year in the field of treatment of RA, with the major aim to let clinicians and researchers reflect on "what is new", "what is effective" and "what is safe".
Articolo in rivista - Review Essay
rheumatoid arthritis; treatment;
English
519
534
16
Silvagni, E., Di Battista, M., Bonifacio, A., Zucchi, D., Governato, G., Scire, C. (2019). One year in review 2019: novelties in the treatment of rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 37(4), 519-534.
Silvagni, E; Di Battista, M; Bonifacio, A; Zucchi, D; Governato, G; Scire, C
File in questo prodotto:
File Dimensione Formato  
Silvagni et al. - 2019 - One year in review 2019 novelties in the treatmen.pdf

accesso aperto

Descrizione: articolo principale - free to view
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 350.67 kB
Formato Adobe PDF
350.67 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/355210
Citazioni
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 33
Social impact